More like $20. 6 ph 2 and ph 3 candidates, higher sales.
Break even used to be $400 million. Now that $125 M in costs has been reduced, that means its more like $275 million. Do the math, $275 million divided by $93k per treatment, is 2956 or around 3,000 patients per year. Significantly less than 20k patients ! See the upside once this catches on the upside is amazing. 240,000 new cases a year are prognosed so if we h it 10 % of those with provenge, its more like 24000 * 93000 = $2.2 Billion is potential.
WOuldnt surprise me at all. During the CC yesterday they even said "we are considering all strategic options." And they did not deny or confirm buyout, just said no comment which is wall street way of saying yes. $20 is the price. Mark it. FDA and EU seals it.
Agreed. Provenge and immunotherapy in general is a paradigm shift in cancer treatment. There are very powerful vested interests who want to maintaint he status quo of chemo. In time DNDN will be blockbuster . Mark it.
Results were from ASCO in Chicago , Annual Meeting of the American Society of Clinical Oncology, or ASCO, taking place June 1-5, 2012 in Chicago, Illinois.
PS Theodore Cohen has a PhD, unlike some of the schmuck shorts that post on this board he is very smart ! I will listen to him over a short any day !
Take a look at Theodore Cohen's May 17 2012 write up in Seeking Alpha. Although not statistically significant, it shows 13 months median OS for those men who have PSA 22.1 or less...in other words those men who have less advanced disease have a better immune response, which translates into higher survival. So the 4 motnhs survival is correct but under right conditions can be 13 months.
"when you look at the trends in the data, the lower the Baseline PSA, the greater is the magnitude of the life extension benefit. In the case of a patient with a Baseline PSA less than or equal to 22.1, the median life extension benefit is a stunning 13.0 months. Put another way, those men with less advanced disease may benefit more from treatment with sipuleucel-T."
Wow another ID created today huh? Ignore button you go !
There will be a bidding war for DNDN. Mark it. Do not sell on first buyout offer. Final buyout will be $20-30/share.
DNDN will be breaking out soon. Just watch and learn. This is recovering now PPS is slowly creeping upwards. Shorts need to realize sales increase, COGS reduction, EU approval, other products, other markets all will cause pop to teens IMHO.
They can't say "yes" because if it doesn't happen they can be sued. They can't say "no" because if it happens they can be sued. Onlly thing they can say is "no comment." Yes htis is a HUGE confirmation ! Look for $15-20/share YEEESSSS!!!!